The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2

Annals of Oncology

Volumn 11, Issue 6, 2000, Pages 647-663

  Hamilton, A ^a   Piccart, M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BCL 2; Breast cancer; HER 2; p53; Predictive factor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOCETAXEL; DOXORUBICIN; DROLOXIFENE; FADROZOLE; GOSERELIN; MEGESTROL ACETATE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; ONCOPROTEIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; TUMOR PROTEIN; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; DISEASE MARKER; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT INDICATION;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; FEMALE; FORECASTING; HUMANS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033744498     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008390429428     Document Type: Review

References (68)

1. Polychemotherapy for early breast cancer: An overview of the randomised trials
2. Hormonal therapy and chemotherapy
3. Tamoxifen for early breast cancer: An overview of the randomised trials
4. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
5. Overall survival advanvtage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody herceptin in HER2-overexpressing metastatic breast cancer
6. The hunt for ras targets
7. Apoptosis meets signal transduction: Elimination of a BAD influence
8. Controlling cell death
9. Estrogen-dependent tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER-2/neu
10. Possible mechanisms in the emergence of tamoxifen-resistant breast cancer
11. The regulation of p53 function: Steiner Award Lecture
12. Molecular epidemiology
13. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
14. p53 status and the efficacy of cancer therapy in vivo
15. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells
16. Double identity for proteins of the BCL-2 family
17. The release of cytochrome c from mitochondria: A primary site for BCL-2 regulation of apoptosis
18. Identification of an estrogen response element activated by metabolites of 17b-estradiol and raloxifene
19. BCL-2 prolongs cell survival after Bax-induced release of cytochrome c
20. Injected cytochrome c induces apoptosis
21. Lymphocytic lymphomas
22. BCL-2 family proteins: Regulators of apoptosis and chemoresistance in hematological malignancies
23. Expression of BCL-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy
24. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
25. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers
26. Elevated serum c-erb-B2 antigen levels and decreased response to hormone therapy of breast cancer
27. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study
28. Prediction of response to antioestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
29. c-erb-B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
30. Relationship between EGF-R, c-erb-B2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity
31. Expression of ras p21, p53 and c-erb-B2 in advanced breast cancer and response to first line hormonal therapy
32. erbB-2 and response to doxorubicin in patients with axillary lymph node positive, hormone receptor negative breast cancer
33. c-erb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer
34. erbB-2, p53, and efficacy of adkuvant therapy in lymph node positive breast cancer
35. p53 accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
36. No significant predictive value of c-erb-B2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
37. Predictive value of c-erb-B2, p53, cathepsin D and histology of the primary tumour in metastatic breast cancer
38. Relationship between c-erb-B2 protein product expression and response to endocrine therapy in advanced breast cancer
39. Prognostic Importance of c-erb-B2 expression in breast cancer
40. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
41. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
42. BCL-2, p53 and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study
43. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer
44. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
45. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil and prednisone for breast cancer
46. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated perioperatively with continuous infusion 5-fluorouracil and radiation therapy
47. p53 expression and the result of adjuvant therapy of breast cancer
48. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
49. Expression of drug resistance in breast cancer, in relation to chemotherapy
50. Expression of p53, glutathione S-transferase-p and BCL-2 proteins and benefit from adjuvant radiotherapy in breast cancer
51. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: A novel hypothesis based on clinical findings
52. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity
53. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up
54. Benefit of CMF treatment in lymph node-positive breast cancer overexpressing HER-2
55. ErbB-2 overexpression and response to chemotherapy - NSABP study
56. CMF or anthracycline-based chemotherapy for node-positive breast cancer patients: Four-year results of a Belgian randomised clinical trial with predictive markers analysis
57. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast cancer
58. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer
59. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
60. Expression of epidermal growth factor receptor and c-erbB-2 during the development of tamoxifen resistance in human breast cancer
61. Prognostic and predictive value of c-erb-B2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
62. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer
63. Response to mitoxantrone in advanced breast cancer: Correlation with expression of c-erb-B2 protein and glutathione S-transferases
64. Plasma c-erb-B2 concentrations in relation to chemotherapy in breast cancer patients
65. Breast cancer response to adjuvant chemotherapy in correlation with erb-B2 and p53 expression
66. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
67. p53 and BCL-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients
68. BCL-2 protein in invasive ductal breast carcinomas